Explore more publications!
Boston Technology Review
Got News to Share?

Press Releases

Blacksmith Agency Reports Rising Demand for Custom Web Infrastructure Among Local Firms in Boston
Jan. 29, 2026

Blacksmith Agency Reports Rising Demand for Custom Web Infrastructure Among Local Firms in Boston

Neutral EIN Presswire
Ataccama Named a Leader in Data Quality Solutions Report by Independent Research Firm
Jan. 28, 2026

Ataccama Named a Leader in Data Quality Solutions Report by Independent Research Firm

Indeterminate GlobeNewswire, Inc.
Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site
Jan. 28, 2026

Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site

Indeterminate GlobeNewswire, Inc.
Former Finance Director Launches Fractional CFO and Bookkeeping Practice in Greater Boston
Jan. 29, 2026

Former Finance Director Launches Fractional CFO and Bookkeeping Practice in Greater Boston

Neutral EIN Presswire
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
Feb. 18, 2026

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory

Indeterminate GlobeNewswire, Inc.
Vystar Announces 2-Week-Long Memorabilia Sweepstakes on X Platform
Feb. 18, 2026

Vystar Announces 2-Week-Long Memorabilia Sweepstakes on X Platform

Indeterminate GlobeNewswire, Inc.
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
Jan. 28, 2026

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

Indeterminate GlobeNewswire, Inc.
BCC Research Reports Highlight Markets Exceeding 25%+ CAGR
Jan. 28, 2026

BCC Research Reports Highlight Markets Exceeding 25%+ CAGR

Indeterminate GlobeNewswire, Inc.
Myseum Announces Gold Sponsorship of The Photo Managers 2026 Boston Conference, Launches North American User Acquisition Campaign
Jan. 28, 2026

Myseum Announces Gold Sponsorship of The Photo Managers 2026 Boston Conference, Launches North American User Acquisition Campaign

Indeterminate GlobeNewswire, Inc.
Globally Acclaimed Michelangelo’s Sistine Chapel: The Exhibition ® Premieres in Boston
Jan. 29, 2026

Globally Acclaimed Michelangelo’s Sistine Chapel: The Exhibition ® Premieres in Boston

Indeterminate GlobeNewswire, Inc.
Imviva Biotech Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma
Jan. 27, 2026

Imviva Biotech Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma

Indeterminate GlobeNewswire, Inc.
Whey Protein Products: Powering Performance and Nutrition Across Global Markets
Feb. 17, 2026

Whey Protein Products: Powering Performance and Nutrition Across Global Markets

Indeterminate GlobeNewswire, Inc.
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
Jan. 27, 2026

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire, Inc.
px Saltend Chemicals Park Named as Home to LanzaTech’s Groundbreaking DRAGON II Sustainable Aviation Fuel Project, Set to Create SAF Jobs on the Humber
Jan. 28, 2026

px Saltend Chemicals Park Named as Home to LanzaTech’s Groundbreaking DRAGON II Sustainable Aviation Fuel Project, Set to Create SAF Jobs on the Humber

Indeterminate GlobeNewswire, Inc.
Toll Brothers Reports FY 2026 First Quarter Results
Feb. 17, 2026

Toll Brothers Reports FY 2026 First Quarter Results

Indeterminate GlobeNewswire, Inc.
MediWound to Present at Upcoming Investor Conferences
Feb. 17, 2026

MediWound to Present at Upcoming Investor Conferences

Indeterminate GlobeNewswire, Inc.
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
Feb. 17, 2026

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

Indeterminate GlobeNewswire, Inc.
Valiant Funds Announces Availability of Fund IV on Charles Schwab
Feb. 17, 2026

Valiant Funds Announces Availability of Fund IV on Charles Schwab

Neutral EIN Presswire
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Feb. 17, 2026

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Indeterminate GlobeNewswire, Inc.
Experts Warn AI-Generated Media on Social Platforms Fuels False Memories
Feb. 17, 2026

Experts Warn AI-Generated Media on Social Platforms Fuels False Memories

Indeterminate MENAFN
Owner: Sawsan Dababneh & Ramzi AbdelJaber

MENAFN

Indeterminate
Owned By Sawsan Dababneh & Ramzi AbdelJaber through The Middle East North Africa Financial Network, Inc
Year Founded 2000
Website menafn.com
Domain Registration Year Indeterminate
Access Type open
Publication Location Amman, New York, Dubai

We welcome your feedback!
If you have comments or corrections, let us know.

Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions